Pharma Freebies to Doctors: Supreme Court Pushes for Stronger Marketing Rules
The Supreme Court has directed the Centre to form an expert committee to examine stronger rules against unethical pharmaceutical marketing. The move could pave the way for legally enforceable penalties for companies offering inducements to influence doctors’ prescriptions.
The Supreme Court has directed the Centre to establish an expert committee to examine stronger rules against unethical pharmaceutical marketing, including freebies and incentives linked to doctors’ prescriptions.
The committee must be constituted within two weeks and consult petitioners, intervenors and other stakeholders. It must submit recommendations within two months of its first meeting, after which the government will consider the proposals and report back to the court.
The order follows a long-running legal battle over whether India’s pharmaceutical marketing rules have sufficient enforcement powers. The Federation of Medical and Sales Representatives’ Associations of India (FMRAI), which filed the petition in 2021, has argued that voluntary industry oversight cannot adequately prevent companies from influencing prescribing decisions.
The Uniform Code for Pharmaceutical Marketing Practices (UCPMP) governs promotional activities, including gifts, hospitality, travel, sponsorships and free medicine samples offered to healthcare professionals.
A revised version introduced in March 2024 strengthened oversight by requiring ethics officers, compliance undertakings and more structured complaint mechanisms. However, concerns remain over whether the code provides clear statutory powers and effective penalties.
The Centre has acknowledged that the mechanism regulating pharmaceutical companies needs strengthening, while maintaining that existing provisions adequately address the regulation of medical practitioners.
Experts have also raised concerns about indirect payments through intermediary agencies. Such practices, if established, can influence treatment choices and increase patients’ medical expenses.
The expert committee’s recommendations could determine whether India adopts a dedicated law, amends existing legislation or introduces another enforceable regulatory framework. The outcome may shape accountability across the pharmaceutical industry and help protect independent medical decision-making.
